J Heart Lung Transplant

1. CHOW JKL, Vest AR, DeNofrio D, Snydman DR, et al
   Tolerability and Clinical Efficacy of Letermovir for Primary Cytomegalovirus Prophylaxis After Heart Transplantation.
   J Heart Lung Transplant. 2025 Sep 11:S1053-2498(25)02257.
   

   >> Share

   
   

   
   J Virol

2. BARUAH V, O'Connor CM
   The BTK-DDX41 axis of the STING pathway is activated during cytomegalovirus lytic infection.
   J Virol. 2025 Sep 16:e0104825. doi: 10.1128/jvi.01048.
   

   >> Share

   
   
3. KUMAR R, Reider IE, Martin M, Simpson JS, et al
   The HCMV tegument protein UL88 degrades MyD88 and reduces innate immune activation.
   J Virol. 2025;99:e0041425.
   

   >> Share

   
   

   
   Proc Natl Acad Sci U S A

4. LEE J, Manon V, Chen J
   Structurally diverse viral inhibitors converge on a shared mechanism to stall the antigen transporter TAP.
   Proc Natl Acad Sci U S A. 2025;122:e2516676122.
   

   >> Share

   
   

   
   Transplant Proc

5. CAMPBELL A, Pruett TL
   Revisiting the Biological Rationale for Cytomegalovirus Immune Globulin (CMVIG) in the Modern Era of Solid Organ Transplantation: Current State and Future Direction.
   Transplant Proc. 2025 Sep 12:S0041-1345(25)00381.
   

   >> Share

   
   

   
   Transplantation

6. GARDINER BJ, Lee SJ, Snell GI, Westall GP, et al
   Response to Letter: Global Immune Biomarkers and Donor Serostatus Can Predict Cytomegalovirus Infection Within Seropositive Lung Transplant Recipients.
   Transplantation. 2025 Sep 17. doi: 10.1097/TP.0000000000005531.
   

   >> Share

   
   

   
   Virology

7. SATANI KH, Spencer JV
   Human cytomegalovirus interleukin 10 (cmvIL-10) orchestrates crosstalk between the cellular IL-10 receptor and CXCR4.
   Virology. 2025;612:110693.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share